



## ***Helicobacter pylori* Infection and Antibiotic Resistance: The Emerging Eradication Strategies**

Guest Editors:

**Prof. Dr. Tomica Milosavljevic**

Euromedik Hospital Belgrade,  
Belgrade, Serbia

**Dr. László Hersényi**

2nd Department of Medicine,  
Semmelweis University, H-1088  
Budapest, Hungary

Deadline for manuscript  
submissions:

**31 October 2024**

### **Message from the Guest Editors**

Dear Colleagues,

In light of the growing prevalence of *Helicobacter pylori* (*H. pylori*), its eradication has been recognized as high priority. Despite efforts to control this pathogen, several factors have hindered its successful eradication. Antibiotic resistance has been recognized as the main driving factor in the treatment failure process.

The indiscriminate use of antibiotics in both clinical and community settings has played a significant role in fueling this problem, selecting for resistant strains and promoting their proliferation. *H. pylori* has developed an impressive repertoire of resistance mechanisms, rendering traditional antibiotic therapies less effective and highlighting the urgent need for a tailored therapy approach.

By fostering an interdisciplinary approach, implementing stringent antibiotic stewardship programs, and promoting tailored treatment approaches, we can strive toward successful *H. pylori* treatment outcomes.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)